Zoetis gets USDA license for Cytopoint Plus, a 75-day itch injection for dogs
Zoetis has a USDA license for Cytopoint Plus, an injectable antibody it says relieves canine allergic itch for 75 days per dose. Cytopoint is labeled for four to eight weeks, and Elanco's Befrena lists 6 to 8. Zoetis positions the new product alongside Cytopoint and Apoquel.

Zoetis has a USDA license for Cytopoint Plus, an injectable monoclonal antibody that the company says relieves allergic itch in dogs for 75 days from a single dose. A veterinary health professional gives it as one injection, and Zoetis said the antibody targets interleukin-31, a signaling protein involved in itch in dogs with allergic dermatitis.
Zoetis calls Cytopoint Plus the first and only USDA-licensed next-generation monoclonal antibody with 75 days of itch relief. It said the product starts relieving itch within 1 day, and that the studies supporting approval showed efficacy through Day 75 and a safety profile similar to Cytopoint. The company cited the data as on file under Study No. C166R-US-24-617.
"The license of Cytopoint Plus sets a new benchmark in canine dermatology," said Abhay Nayak, Executive Vice President and President, U.S. Commercial Operations at Zoetis. He said the product gives owners "more time focused on their dog, not their dog's treatment schedule."
Seventy-five days runs past the eight-week label
Cytopoint is the existing product. When Zoetis announced its full USDA license in December 2016, the company's own newsroom described dosing as "one injection every four to eight weeks." That release also noted a conditional license granted in August 2015, so the product spent about sixteen months under conditional status before full licensure.
Seventy-five days works out to about 10.7 weeks. By our math, that is 19 days beyond the eight-week end of the Cytopoint range. Zoetis positions Cytopoint Plus alongside Cytopoint and Apoquel, its oral itch medicine, in the dermatology portfolio.
Zoetis tied the longer interval to scheduling. Dr. Lindsay McKay, quoted by the company, said "Frequent vet clinic visits for treating allergic dermatitis can create scheduling hurdles for busy pet caregivers." Dr. Tiffany Tapp, also quoted, said that extending the time between injections may make care "potentially more affordable for some families."
The company described the scale of the condition in its own words. It said allergic dermatitis "is the number one reason pet owners visit their veterinarians," and that itching affects "roughly 1 in 4 dogs whose owners seek veterinary help." Zoetis has been in animal health for "nearly 75 years" and serves customers in more than 100 countries, according to its company description.
The longer interval lands in a crowded itch aisle
Elanco also sells an anti-IL-31 antibody for dogs. It received USDA approval for Befrena in December 2025 and began a phased U.S. launch in May. Elanco's product page for veterinarians lists repeat dosing "every 6-8 weeks or as needed" and says the product has been shown to be safe when given every 4 weeks. The page says Befrena can be used in dogs of all ages and describes its dosing chart as covering dogs from 5 lbs to 120 lbs.
That puts three dosing figures side by side. Cytopoint is labeled for four to eight weeks, Befrena for 6 to 8, and Cytopoint Plus is described by Zoetis at 75 days, or about 10.7 weeks. These are dog products, so the comparison does not carry over to cats.
A longer-acting rival is also in the research pipeline. Akston reported that its investigational AKS-699 matched Cytopoint in a head-to-head challenge study on far fewer injections, as our coverage of the twice-yearly itch shot detailed. That candidate is preclinical, run in an induced itch model, and has no approval.
Zoetis has named the category itself. In its third-quarter results, it reported U.S. companion animal sales of $980M, down 8%, and listed competitive pressure in dermatology among the reasons. Elanco competes on the oral side with Zenrelia, an oral JAK inhibitor that sits against Apoquel, so the two companies now each sell a biologic and an oral drug for canine itch.
Clinics now wait on pricing and a launch date
The people most affected are clinic owners and practice managers who set recheck schedules and stock injectables. A product that covers 75 days changes how often an itchy dog needs to come back for a shot, and McKay's point about missed treatments concerns that visit pattern. Practices that have built reminder workflows around a four- to eight-week cycle would be rebuilding them around a longer one.
For Elanco, the comparison point moves. Befrena's label lists 6 to 8 weeks, and Zoetis now describes an interval that runs past it. For distributors that stock both companies' biologics, a third dosing tier means another product to carry and another set of conversations about which dogs go on which schedule.
Zoetis did not give a price or a launch date for Cytopoint Plus. Those two numbers will decide whether the 75-day interval shows up on clinic shelves in a form that owners of large dogs can afford, which is the group Tapp pointed to when she tied the longer interval to affordability.
Cytopoint Plus puts a 75-day dose in a category where the nearest listed rival label reads 6 to 8 weeks.
Source: Zoetis via Business Wire
Other News
More stories shaping the pet industry this week. From funding rounds and product launches to regulatory shifts and retail strategy, stay ahead of what's driving the market.
